VAL On Other Exchanges
Symbol
Exchange
London

valirx plc (VAL) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALIRX PLC (VAL)
\

Related News

No related news articles were found.

valirx plc (VAL) Related Businessweek News

No Related Businessweek News Found

valirx plc (VAL) Details

ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company’s lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

12 Employees
Last Reported Date: 05/29/19
Founded in 2000

valirx plc (VAL) Top Compensated Officers

Founding Director & CEO
Total Annual Compensation: 213.6K GBP
Founding Director & CFO
Total Annual Compensation: 80.6K GBP
Founding Director & COO
Total Annual Compensation: 177.5K GBP
Secretary & Independent Non-Executive Directo...
Total Annual Compensation: 48.0K GBP
Compensation as of Fiscal Year 2018.
valirx plc
Valirx plc Reports Earnings Results for the Full Year Ended December 31, 2018

ValiRx plc announced earnings results for the full year ended December 31, 2018. For the full year, the company announced operating loss was GBP 3.865 million compared to GBP 3.125 million a year ago. Net loss was GBP 4.298 million compared to GBP 3.019 million a year ago. Basic loss per share was GBP 0.0094 compared to GBP 0.019 a year ago.

ValiRx plc to Form Joint Venture with Alpha Blue Ocean

ValiRx Plc has signed a Letter of Intent (LOI) with Alpha Blue Ocean (ABO) to establish a genetic therapeutic and diagnostic-based Joint Venture (JV). Concurrently, ValiRx has entered into a purchase agreement to acquire the global granted patents and Intellectual Property assets (IP assets) of FIT Biotech OY (FIT Bio) for a consideration of EUR5,000 (USD5,610.82 million. ValiRx will acquire the IP assets from the appointed administrator of FIT Bio. The agreement is to establish a genetic therapeutic and diagnostic-based joint venture (JV), for the further development of FIT Bio's IP assets with the objective to assemble and progress a portfolio of genetic-based technologies. It is envisaged that ValiRx will provide the scientific, technological and clinical development expertise to the JV, whilst ABO will focus on financing the entity and progressing commercial activities. It is also envisaged that ValiRx will add its GeneICE technology, along with the Company's gene silencing compound, VAL101, into the JV portfolio to sit alongside the IP assets of FIT Bio, as the Company believes the portfolio technologies are complementary to each other. formation of the JV is subject to further due diligence following the conclusion of scientific and financial analysis. ValiRx and ABO have agreed that discussions and future negotiation are to be conducted on an exclusive basis.

Valirx plc Announces VAL201 Enters the Concluding Stages of its Phase L/II Clinical Trial

ValiRx Plc announced that VAL201 has now entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital ("UCLH") involving patients with hormone-sensitive and hormone-resistant prostate cancer. This stage of the trial follows approval received from the Medicines and Healthcare products Regulatory Agency ("MHRA") to escalate VAL201 dosing (announced by the Company on18 December 2017). In the intervening period, the Company has geared up the compound supply chain to meet increased demand for the drug, as a result of the higher dosage to be administered. UCLH has spent the period both screening and recruiting patients who are eligible to enter this stage of the study. The current cohort has already received the escalated dose. This marks the point that VAL201 entered the concluding stages of the Phase l/ll clinical trial. The VAL201 compound has already demonstrated consistent safety and tolerability and signs of activity in previous patients treated with lower dosages.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies
 

Industry Analysis

VAL

Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.